.Pharmacolibrary.Drugs.ATC.H.H01CC04 .Pharmacolibrary.Drugs.ATC.H.H01CC04| name: | Linzagolix | |
| ATC code: | H01CC04 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 200 | mg |
| volume of distribution: | 52.6 | L |
| clearance: | 3.64 | L/h |
| other parameters in model implementation | ||
Linzagolix is an oral, selective, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist used for the treatment of uterine fibroids and endometriosis in women of reproductive age. It reduces estrogen levels by suppressing the hypothalamic-pituitary-gonadal axis. Linzagolix is approved in the European Union but not in the United States.
Pharmacokinetic parameters reported in healthy premenopausal women after oral administration.